Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals

Amgen and the University of Texas MD Anderson Cancer Center inked a pair of research deals that will accelerate the development of several early-stage cell therapies and small molecules for blood cancers, small-cell lung cancer and other small-cell cancers.